Newswire (Published: Tuesday, June 6, 2017, Received: Friday, June 2, 2017, 7:01:51 AM CDT)

Word Count: 402

Researchers from Department of Urology Describe Findings in Prostate Cancer (Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis)

By a News Reporter-Staff News Editor at Cancer Weekly -- Investigators publish new report on Oncology - Prostate Cancer. According to news reporting out of Salford, United Kingdom, by NewsRx editors, research stated, "Prostate cancer (PCa) diagnostics are evolving rapidly. The quest to differentiate 'clinically significant' from 'clinically insignificant' disease has gathered momentum, leading to substantial change in traditional diagnostic approaches."

Our news journalists obtained a quote from the research from the Department of Urology, "Herein, we review the relevant information on currently available biomarkers and assess their ability to help physicians and patients in making a shared and personalized decision based on their individual risk of harbouring clinically significant disease. Serum, urine, tissue and imaging biomarkers have been evaluated to improve the identification of clinically significant disease, and this international effort has yielded promising, but not always consistent results. Changes in MRI technology have realized a quantum change, and this facility is now becoming more widely incorporated into diagnostic and disease risk-stratification protocols. However, standardization and further validation is required. Acceptance and widespread adoption of serum, urine and genetic markers is awaited, but novel and promising techniques alone and in combination have emerged."

According to the news editors, the research concluded: "With validation and further focus, these may be adopted more widely."

For more information on this research see: Identification and evaluation of clinically significant prostate cancer: a step towards personalized diagnosis. Current Opinion in Urology, 2017;27(3):217-224. Current Opinion in Urology can be contacted at: Lippincott Williams & Wilkins, Two Commerce Sq, 2001 Market St, Philadelphia, PA 19103, USA. (Lippincott Williams and Wilkins - www.lww.com; Current Opinion in Urology - journals.lww.com/co-urology/pages/default.aspx)

Our news journalists report that additional information may be obtained by contacting N.W. Clarke, Salford NHS Fdn Trust, Dept. of Urol, Salford, Lancs, United Kingdom. Additional authors for this research include A. Hoyle, E. Baena and A. Ali (see also Oncology - Prostate Cancer).

Keywords for this news article include: Salford, United Kingdom, Europe, Cancer, Article Review, Diagnostics and Screening, Risk and Prevention, Prostatic Neoplasms, Prostate Cancer, Oncology, Genetics, Department of Urology.

Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2017, NewsRx LLC

Companies

Lippincott Williams & Wilkins
Wolters Kluwer N.V.
Wolters Kluwer N.V.
Wolters Kluwer N.V.

Places

North America
Northern Europe
United Kingdom
United States
Americas
Europe
England
Pennsylvania
Lancashire
Salford
Philadelphia

Subjects

Science and Technology
      Scientific Research
Health and Wellness
      Medical Conditions and Diseases
            Cancer
                  Prostate Cancer
            Men's Health Issues
                  Prostate Cancer
            Urological Diseases
      Medical Specialties and Practices
            Urology